Yüklüyor......
Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fra...
Kaydedildi:
| Yayımlandı: | J Geriatr Cardiol |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Science Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5253408/ https://ncbi.nlm.nih.gov/pubmed/28133468 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.11909/j.issn.1671-5411.2016.11.006 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|